EluSys is a biopharmaceutical company focused on the development of therapeutic monoclonal antibodies for the prevention and treatment of human diseases with unmet medical needs. EluSys' patented technology, the Heteropolymer, may offer a significant advance in the management and treatment of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the effectiveness of the body's natural defense mechanisms to remove such pathogens from the blood and destroy them. The company's cancer therapeutic is a single monoclonal antibody that shows early promise against a variety of cancers. Founded in 1998, EluSys is headquartered in Pine Brook, NJ.